One obstacle to successful radiotherapy is the elevated resistance to ionizing radiation that many tumors display relative to adjacent normal tissues. Thus the radiosensitivity of normal tissue limits the radiation dose that can be delivered to a tumor. The combined effect of tumor resistance and normal tissue sensitivity can result in incomplete elimination of tumor cells and local recurrence. This grant address this problem by developing a method to specifically sensitize tumor cells to radiation using an approach based on the contribution of ras oncogenes to radiation resistance. Ras oncogenes are frequently mutated in human tumors treated with radiation therapy. These include pancreatic, colon, ovarian, and thyroid carcinomas sarcomas and late stage cervical carcinomas. Ras mutations have furthermore been shown to cause increase radiation resistance in experimental tumor systems. Thus, inhibition of the activity of oncogenic ras might be hypothesized to lead to radiation sensitization of the tumor cells. Since normal cells do not contain oncogenic ras, such an approach should not affect these cells. Farnesyltransferase and geranylgeranyltransferase inhibitors are compounds that specifically inhibit the post-translational prenylation of ras which is required for membrane association and signal transduction activity. The action of farnesyltransferase inhibitors (FTI) appears to be greatest against activated H-ras oncogenes, and consequently little or no effect is seen in normal cells as doses that significantly alter the morphology, growth and radiation-resistance of H-ras transformed cells. Geranylgeranyltransferase inhibitors (GGTI) show selective activity against K-ras prenylation. Both inhibitors have been shown to impede tumor growth, and are thus ideal candidates for combined modality therapy with radiation. The goal of this study is to determine whether the specificity of these inhibitors for the activated ras in tumor cells can be exploited such that these agents can be used as tumor cell radiosensitizers during radiation therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA073820-01A1
Application #
2467975
Study Section
Radiation Study Section (RAD)
Program Officer
Mahoney, Francis J
Project Start
1997-12-12
Project End
2001-11-30
Budget Start
1997-12-12
Budget End
1998-11-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Qayum, Naseer; Im, Jaehong; Stratford, Michael R et al. (2012) Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 18:161-9
Maity, Amit; Bernhard, Eric J (2010) Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 70:2141-5
Hamilton, Julie; Higgins, Geoff; Bernhard, Eric J (2009) Conventional radiotherapy or hypofractionation? A study of molecular changes resulting from different radiation fractionation schemes. Cancer Biol Ther 8:774-6
Qayum, Naseer; Muschel, Ruth J; Im, Jae Hong et al. (2009) Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 69:6347-54
Cordes, N; Frick, S; Brunner, T B et al. (2007) Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26:6851-62
Cengel, Keith A; Voong, K Rahn; Chandrasekaran, Sanjay et al. (2007) Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9:341-8
Jiang, Zibin; Pore, Nabendu; Cerniglia, George J et al. (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67:4467-73
Kim, In-Ah; Bae, Sun-Sik; Fernandes, Annemarie et al. (2005) Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65:7902-10
Brunner, Thomas B; Cengel, Keith A; Hahn, Stephen M et al. (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 65:8433-41
Martin, Neil E; Brunner, Thomas B; Kiel, Krystina D et al. (2004) A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 10:5447-54

Showing the most recent 10 out of 21 publications